Latest Conference Articles

If patients with cancer experience depression or anxiety, it can result in low clinical trial enrollment.

Tisagenlecleucel evoked similar efficacy and a preferrable safety profile in children and adults with B-ALL being treated in a real-world analysis, compared with the clinical trial ELIANA.

In comparison to physicians’ choice of treatment, ciltacabtagene autoleucel demonstrated significant advantages in progression-free and overall survival, time to next treatment, and overall response rate.

Combining ibrutinib with rituximab resulted in improved 2-year progression-free survival among elderly patients with previously untreated diffuse large B-cell lymphoma.

Findings presented at the 2021 San Antonio Breast Cancer Symposium suggest that Certain adverse effects associated with olaparib were minimal and resolved with appropriate management in patients with breast cancer.

Findings from a breast cancer analysis demonstrated that pathologic complete response and event-free survival rates were not significantly affected by patient’s race.

The introduction of adjuvant approaches reduced the risk of disease recurrence in HER2-positive, early-stage breast cancer.

Treatment modifications were inconsistent among White and Black patients with breast cancer. However, the use of a multiscale biophysical modeling platform may be useful in informing treatment modification decisions.

Findings from a pooled efficacy and safety analysis support the use of palbociclib plus endocrine therapy in patients who are Black or Hispanic with hormone receptor–positive, HER2-negative breast cancer.

Aromatase inhibitors were revealed to be more effective than tamoxifen in reducing the rate of recurrence in ER+ breast cancer among premenopausal women receiving ovarian suppression.

The 24-month lymphedema rate was 39.4% among Black women, making it the highest incidence rate in any category.

Patients who received matched targeted therapy specific to their genomic alteration, as identified through multigene sequencing, experienced significantly improved progression-free survival.

A retrospective study presented at the 22nd SUO Annual Meeting revealed that pelvic organ–preserving robot-assisted radical cystectomy allowed women to return to sexual activity post-surgery.

Hispanics are the largest ethnic minority and one of the most rapidly growing populations in the United States. Prostate cancer represents the highest incident non-cutaneous malignancy in this population.

A secondary analysis of 2 treatment alterations studies demonstrated that 18F-fluciclovine PET/CT scans play a pivotal role in determining if androgen deprivation therapy is appropriate for patients with prostate cancer.

A study presented at the 22nd SUO Annual Meeting did not identify any significant or clinically meaningfully differences in HRQOL in patients with nonmetastatic bladder cancer who receive robotic-assisted vs open radical cystectomy.

Urine cytology specimen NGS was found to be a feasible and valid method of assessing genomic alterations in patients with upper tract urothelial carcinoma.

A presentation at the SUO Annual Meeting underscored best surveillance strategies for patients with low-grade upper tract urothelial carcinoma who have undergone radical nephroureterectomy.

The addition of bevacizumab was found to boost responses in patients with epithelial ovarian cancer receiving pembrolizumab.

Patients with relapsed/refractory chronic lymphocytic leukemia experienced positive gene set enrichment after receiving ibrutinib in addition to lisocabtagene maraleucel.

Pooled findings indicate that the quality of life in patients receiving surufantinib for advanced neuroendocrine tumors was comparable to that of placebo.

Patients with neuroendocrine tumors across various origins experienced favorable responses after receiving tidutamab.

An expert from NYU Langone outlines how checkpoint blockade approvals have helped advance endometrial cancer management.

The COVID-19 pandemic has demonstrated that personalized medicine should consider social determinants of health disparities as well as genomic factors.

Patients with cancer should receive the entire COVID-19 vaccination as soon as possible, according to an expert at the 39th Annual Chemotherapy Foundation Symposium.

Findings from biomarker tests for patients with chronic lymphocytic leukemia can help appropriately tailor therapy plans as well as identify patients eligible for clinical trials.

Newer modalities seek to use MRD to provide more definitive prognoses.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, comments on how health care providers can effectively care for patients with COVID-19 and hematologic malignancies.

A speaker at the Oncology Nursing Society Bridge Program discussed how nurses can build their own resilience and proactively protect their mental well-being.

An expert on immune toxicity management discusses dermatologic, gastrointestinal, hepatic, and endocrine irAEs and how nurses can help educate their patients to monitor these symptoms.